Statins and cognition: What can we learn from existing randomized trials?

Glen Xiong, Aaron Benson, P. Murali Doraiswamy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Statins are being developed as treatments for Alzheimer's dementia based on evidence from preclinical and observational studies. However, cholesterol plays an integral role in cell membrane signal transduction and suboptimal cholesterol level could potentially impair neuronal function. Additionally, results of observational nonrandomized studies may have been affected by treatment bias. Methods: We performed a systematic literature review in MEDLINE from January 1966 to July 2004 and included published prospective, randomized, and placebo-controlled human studies that examined the cognitive effects of statins. Results: Nine studies with sample sizes ranging from 22 to 20,000 and duration of 3 weeks to 5 years, met criteria for review. Study populations and cognitive outcomes varied. Four studies were ≥6 months or longer. Overall, none of these studies reported finding a positive benefit for any statin on cognition in non-demented subjects although there was inconsistent evidence for acute cognitive worsening in some studies. Conclusion: While statins intuitively have appeal for the prevention or treatment of dementia, any conclusions about their efficacy should await more definitive evidence from on-going prospective clinical trials.

Original languageEnglish (US)
Pages (from-to)867-874
Number of pages8
JournalCNS Spectrums
Volume10
Issue number11
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cognition
Observational Studies
Cholesterol
MEDLINE
Sample Size
Dementia
Signal Transduction
Alzheimer Disease
Therapeutics
Placebos
Cell Membrane
Clinical Trials
Population

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Xiong, G., Benson, A., & Doraiswamy, P. M. (2005). Statins and cognition: What can we learn from existing randomized trials? CNS Spectrums, 10(11), 867-874.

Statins and cognition : What can we learn from existing randomized trials? / Xiong, Glen; Benson, Aaron; Doraiswamy, P. Murali.

In: CNS Spectrums, Vol. 10, No. 11, 11.2005, p. 867-874.

Research output: Contribution to journalArticle

Xiong, G, Benson, A & Doraiswamy, PM 2005, 'Statins and cognition: What can we learn from existing randomized trials?', CNS Spectrums, vol. 10, no. 11, pp. 867-874.
Xiong G, Benson A, Doraiswamy PM. Statins and cognition: What can we learn from existing randomized trials? CNS Spectrums. 2005 Nov;10(11):867-874.
Xiong, Glen ; Benson, Aaron ; Doraiswamy, P. Murali. / Statins and cognition : What can we learn from existing randomized trials?. In: CNS Spectrums. 2005 ; Vol. 10, No. 11. pp. 867-874.
@article{38575fc9075b4375a8e320ad49c853fc,
title = "Statins and cognition: What can we learn from existing randomized trials?",
abstract = "Background: Statins are being developed as treatments for Alzheimer's dementia based on evidence from preclinical and observational studies. However, cholesterol plays an integral role in cell membrane signal transduction and suboptimal cholesterol level could potentially impair neuronal function. Additionally, results of observational nonrandomized studies may have been affected by treatment bias. Methods: We performed a systematic literature review in MEDLINE from January 1966 to July 2004 and included published prospective, randomized, and placebo-controlled human studies that examined the cognitive effects of statins. Results: Nine studies with sample sizes ranging from 22 to 20,000 and duration of 3 weeks to 5 years, met criteria for review. Study populations and cognitive outcomes varied. Four studies were ≥6 months or longer. Overall, none of these studies reported finding a positive benefit for any statin on cognition in non-demented subjects although there was inconsistent evidence for acute cognitive worsening in some studies. Conclusion: While statins intuitively have appeal for the prevention or treatment of dementia, any conclusions about their efficacy should await more definitive evidence from on-going prospective clinical trials.",
author = "Glen Xiong and Aaron Benson and Doraiswamy, {P. Murali}",
year = "2005",
month = "11",
language = "English (US)",
volume = "10",
pages = "867--874",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "11",

}

TY - JOUR

T1 - Statins and cognition

T2 - What can we learn from existing randomized trials?

AU - Xiong, Glen

AU - Benson, Aaron

AU - Doraiswamy, P. Murali

PY - 2005/11

Y1 - 2005/11

N2 - Background: Statins are being developed as treatments for Alzheimer's dementia based on evidence from preclinical and observational studies. However, cholesterol plays an integral role in cell membrane signal transduction and suboptimal cholesterol level could potentially impair neuronal function. Additionally, results of observational nonrandomized studies may have been affected by treatment bias. Methods: We performed a systematic literature review in MEDLINE from January 1966 to July 2004 and included published prospective, randomized, and placebo-controlled human studies that examined the cognitive effects of statins. Results: Nine studies with sample sizes ranging from 22 to 20,000 and duration of 3 weeks to 5 years, met criteria for review. Study populations and cognitive outcomes varied. Four studies were ≥6 months or longer. Overall, none of these studies reported finding a positive benefit for any statin on cognition in non-demented subjects although there was inconsistent evidence for acute cognitive worsening in some studies. Conclusion: While statins intuitively have appeal for the prevention or treatment of dementia, any conclusions about their efficacy should await more definitive evidence from on-going prospective clinical trials.

AB - Background: Statins are being developed as treatments for Alzheimer's dementia based on evidence from preclinical and observational studies. However, cholesterol plays an integral role in cell membrane signal transduction and suboptimal cholesterol level could potentially impair neuronal function. Additionally, results of observational nonrandomized studies may have been affected by treatment bias. Methods: We performed a systematic literature review in MEDLINE from January 1966 to July 2004 and included published prospective, randomized, and placebo-controlled human studies that examined the cognitive effects of statins. Results: Nine studies with sample sizes ranging from 22 to 20,000 and duration of 3 weeks to 5 years, met criteria for review. Study populations and cognitive outcomes varied. Four studies were ≥6 months or longer. Overall, none of these studies reported finding a positive benefit for any statin on cognition in non-demented subjects although there was inconsistent evidence for acute cognitive worsening in some studies. Conclusion: While statins intuitively have appeal for the prevention or treatment of dementia, any conclusions about their efficacy should await more definitive evidence from on-going prospective clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=28944455358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944455358&partnerID=8YFLogxK

M3 - Article

C2 - 16273014

AN - SCOPUS:28944455358

VL - 10

SP - 867

EP - 874

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 11

ER -